Who are Lipaglyn's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lipanor, Lipavil, fenofibrate/omega, ANTARA® (fenofibrate), Icosapent, duvie.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/saroglitazar.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lipaglyn — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lipaglyn (SAROGLITAZAR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Peroxisome proliferator-activated receptor alpha Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Lipaglyn (SAROGLITAZAR) — Cadila Healthcare.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lipaglyn TARGET	SAROGLITAZAR	Cadila Healthcare	marketed		Peroxisome proliferator-activated receptor alpha
Lipanor	CIPROFIBRATE	Winthrop Pharmaceuticals UK Limited	marketed	ciprofibrate	Peroxisome proliferator-activated receptor alpha	1985-01-01
Lipavil	CLOFIBRATE		marketed	clofibrate	Peroxisome proliferator-activated receptor alpha	1967-01-01
fenofibrate/omega	fenofibrate/omega	Gachon University Gil Medical Center	marketed	Fibrate + omega-3 fatty acid combination	PPARα (peroxisome proliferator-activated receptor alpha)
ANTARA® (fenofibrate)	ANTARA® (fenofibrate)	Ranbaxy Laboratories Limited	marketed	Fibrate (PPARα agonist)	PPARα (Peroxisome proliferator-activated receptor alpha)
Icosapent	Eicosapentaenoic acid	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	marketed		Peroxisome proliferator-activated receptor alpha
duvie	duvie	Pusan National University Hospital	marketed		Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lipaglyn — Competitive Intelligence Brief. https://druglandscape.com/ci/saroglitazar. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing